Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557939 | 0.94 | LMNA (0.34) | LMNATAAR1ALDH1A1GAAMAPT | |
| SCHEMBL5558060 | 0.87 | LMNA (0.38) | LMNAPOLBNPC1MITFRAB9A | |
| SCHEMBL29366012 | 0.87 | LMNA (0.40) | LMNAALDH1A1MAPTPOLBATM | |
| SCHEMBL31733909 | 0.85 | LMNA (0.39) | LMNAALDH1A1POLBATM | |
| SCHEMBL12108939 | 0.79 | L3MBTL1 (0.42) | ALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL5558055 | 0.78 | NPC1 (0.47) | LMNAALDH1A1POLBNPC1MITF | |
| SCHEMBL2100566 | 0.78 | L3MBTL1 (0.50) | ALDH1A1POLBTDP1 | |
| SCHEMBL4090761 | 0.76 | NAAA (0.51) | ALDH1A1POLBTDP1 | |
| SCHEMBL1892070 | 0.76 | NAAA (0.51) | ALDH1A1POLBTDP1 | |
| SCHEMBL149820 | 0.76 | NAAA (0.51) | ALDH1A1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220746-B2 | Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors | ALTANA PHARMA AG (DE) | 2007-05-22 | — | — | US | disclosed |
| EP-1537100-B1 | PYRROLIDINEDIONE SUBSTITUTED PIPERIDINE-PHTHALAZONES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2007-04-25 | — | — | EP | disclosed |
| US-20060160813-A1 | Pyrrolidinedione substituted piperidine-phtalazones as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-07-20 | — | — | US | disclosed |
| EP-1537100-A1 | PYRROLIDINEDIONE SUBSTITUTED PIPERIDINE-PHTHALAZONES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004018457-A1 | PYRROLIDINEDIONE SUBSTITUTED PIPERIDINE-PHTHALAZONES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160813-A1 | Pyrrolidinedione substituted piperidine-phtalazones as pde4 inhibitors | PDE4A, PDE4B, PDE3B | LMNA 3936/4885TAAR1 1595/4885ALDH1A1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.